plasma glucose concentrations bezafibrate patients NIDDM goal study treatment bezafibrate improves tolerance non-insulin-dependent diabetes NIDDM study NIDDM patients concentrations normal kidney liver function diet sulfonylurea drug patient withdrew constipation randomization mo treatment patients standard mixed-test-meal tolerance test MTT cal overnight fast plasma glucose insulin C-peptide metabolite nonesterified fatty acid NEFA triglyceride concentrations intervals Serum lipid fructosamine concentrations monthly intervals Glucose NEFA triglyceride concentrations second MTT bezafibrate patients placebo group serum insulin C-peptide levels postprandial concentrations bezafibrate patients mo mean serum triglyceride concentrations mM total serum cholesterol concentrations mM low-density lipoprotein cholesterol concentrations mM bezafibrate patients changes serum lipid concentrations placebo group Treatment patients NIDDM bezafibrate improves tolerance serum lipid profile Bezafibrate treatment useful adjunct therapy patients NIDDM 